Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563368 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
A Phase 3 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
NCT00563368 is a Phase 3 study that has completed, run by VIVUS. The registered enrollment target is 756 participants.
The verdict
NCT00563368, a Phase 3 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
Interventions
- DRUG VI-0521
- DRUG topiramate
- DRUG phentermine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563368
The ClinicalTrials.gov registry entry for NCT00563368 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VI-0521 is the first listed.
NCT00563368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563368 about?
NCT00563368 is a clinical study titled "A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults". The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater t...
What is the current status of trial NCT00563368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2007-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00563368?
The interventions under investigation include: VI-0521 (DRUG), topiramate (DRUG), phentermine (DRUG).
Who is sponsoring clinical trial NCT00563368?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.